Please login to the form below

Not currently logged in

Transition halts diabetes drug development

Transition Therapeutics has discontinued development of a new therapy for type 2 diabetes after it failed to meet efficacy endpoints

Transition Therapeutics has discontinued development of a potential new therapy for type 2 diabetes after it failed to meet the efficacy endpoints in a late-stage clinical study. The drug, gastrin analogue TT-223, was being tested in combination with a GLP-1 analogue that Transition licensed from Lilly.

"While TT-223 has shown efficacy through development, these results indicate that it does not have the product profile for a diabetes therapy," the company said.

The randomised, double-blind study enroled 150 patients who received either a placebo regimen or daily doses of TT-223 in combination with weekly doses of GLP-1 analogue for four weeks. The study also included a five-month follow-up period.

Transition said its broad in-licensing and collaboration agreement with Lilly will not be affected by the termination of the TT-223 development programme. The deal, which was announced in March of this year, gives Transition exclusive worldwide rights to a series of Lilly's pre-clinical drug candidates for diabetes and related co-morbid conditions. Lilly retains the option to re-acquire the rights to the compounds later in their development.

The Lilly drugs represent a new class of compounds that, in pre-clinical diabetes models, showed potential to provide glycaemic control and weight loss.

The deal signed this year built on a pre-existing partnership between the two companies in the area of gastrin-based therapies for diabetes developed by Transition. That collaboration, which was formed in 2008, granted Lilly exclusive worldwide rights to develop and commercialise Transition's gastrin based therapies, including TT-223.

Toronto-based Transition does not yet have any marketed products. Its lead product in development is a phase III drug for Alzheimer's disease.

21st September 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Market Access Transformation

MAT offers an information exchange called Rapid Payer Response that allows healthcare stakeholders to secure immediate, global, expert insight and...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...